This clinical trial is focused on studying a type of cancer called Mantle-Cell Lymphoma, which is a rare form of non-Hodgkin’s lymphoma. The study is exploring the effectiveness of different treatment combinations for patients who have either not been treated before or have a form of the disease that has returned or is resistant to previous treatments. The treatments being tested include a combination of medications: Glofitamab, Venetoclax, and Zanubrutinib. Glofitamab is given as an infusion, which means it is administered directly into the bloodstream through a vein, while Venetoclax and Zanubrutinib are taken orally as tablets or capsules.

The purpose of the study is to evaluate how well these treatments work in managing high-risk Mantle-Cell Lymphoma. Participants in the study will receive one of the treatment combinations and will be monitored over a period to see how their disease responds. The study will involve regular visits to the clinic for treatment and check-ups, which may include imaging tests to assess the progress of the disease. The study aims to determine the effectiveness of these treatments in controlling the disease and improving patient outcomes.

Throughout the study, participants will be closely observed for any side effects or changes in their condition. The study will help researchers understand the potential benefits and risks of these treatment combinations for Mantle-Cell Lymphoma. The information gathered from this study could contribute to developing better treatment strategies for this type of cancer in the future.